分子分型指导肌层浸润型膀胱癌治疗的研究进展

吴睿成; 白云金; 唐寅; 韩平

doi:10.13201/j.issn.1001-1420.2021.08.016

分子分型指导肌层浸润型膀胱癌治疗的研究进展

- 四川大学华西医院泌尿外科四川大学华西医院泌尿外科研究所(成都, 610041)
基金项目:
四川大学华西医院学科卓越发展1·3·5工程项目(No:ZY2016104)

详细信息

通讯作者: 韩平,E-mail:hanpingwch@163.com

中图分类号: R737.14

收稿日期: 2020-08-01

Advance of molecular classification to guide the treatment of muscular invasive bladder cancer

- Department of Urology, Institute of Urology, West China Hospital, Chengdu, 610041, China

More Information

Corresponding author: HAN Ping, E-mail: hanpingwch@163.com

Received Date: 01 August 2020

摘要

摘要: 膀胱癌是全球第十大最常见的肿瘤,大概四分之一的患者初诊即被确诊为肌层浸润性膀胱癌(muscular invasive bladder cancer,MIBC),其恶性程度较高,且易发生转移。根据指南,目前根治性膀胱切除术(radical cystectomy,RC)是MIBC的一线治疗方案。但随着治疗水平的进步,有研究证实保留膀胱的三联疗法、新辅助化疗、免疫治疗以及靶向治疗可以改善部分MIBC患者的预后,但目前仍缺乏有效的手段筛选出这部分患者。随着分子生物学技术的发展,多个研究中心将MIBC分为不同的分子亚型,并针对各亚型的临床病理特点进行研究,发现不同亚型MIBC对现有各治疗手段的敏感性存在很大差异。这或许可以为治疗策略的选择提供参考,推动个性化治疗的发展。本文就分子分型指导肌层浸润型膀胱癌治疗的研究进展进行综述。
- 膀胱肿瘤 /
- 分子分型 /
- 预后
Abstract: Bladder cancer is the tenth most common tumor in the world. About a quarter of patients are diagnosed with muscular invasive bladder cancer(MIBC), which is highly malignant and prone to metastasis. According to the guidelines, radical cystectomy(RC) is currently the first-line treatment for MIBC. However, studies have confirmed that trimodal therapy with bladder preservation, neoadjuvant chemotherapy, immunotherapy, and targeted therapy can improve the prognosis of some MIBC patients, but there is no effective means to screen out these patients. With the development of molecular biology technology, many research centers have divided MIBC into different molecular subtypes, and conducted research on the clinicopathological characteristics of each subtype. The study found that the sensitivity of different subtypes of MIBC to existing treatments is very different. This may provide a reference for the selection of treatment strategies and promote the development of personalized treatment. This article reviews the progress of molecular classification to guide the treatment of MIBC.
- bladder cancer /
- molecular subtype /
- prognosis

HTML全文

参考文献(24)

[1]	Bray F,Ferlay J,Soerjomataram I,et al.Global cancer statistics 2018:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2018,68(6):394-424.
[2]	Chen W,Zheng R,Baade PD,et al.Cancer statistics in China,2015[J].CA Cancer J Clin,2016,66(2):115-132.
[3]	Kamat AM,Hahn NM,Efstathiou JA,et al.Bladder cancer[J].Lancet,2016,388(10061):2796-2810.
[4]	Warrick JI,Sjödahl G,Kaag M,et al.Intratumoral Heterogeneity of Bladder Cancer by Molecular Subtypes and Histologic Variants[J].Eur Urol,2019,75(1):18-22.
[5]	Aine M,Eriksson P,Liedberg F,et al.Biological determinants of bladder cancer gene expression subtypes[J].Sci Rep,2015,5:10957.
[6]	Milowsky MI,Rumble RB,Booth CM,et al.Guideline on Muscle-Invasive and Metastatic Bladder Cancer(European Association of Urology Guideline):American Society of Clinical Oncology Clinical Practice Guideline Endorsement[J].J Clin Oncol,2016,34(16):1945-1952.
[7]	Efstathiou JA,Spiegel DY,Shipley WU,et al.Long-term outcomes of selective bladder preservation by combined-modality therapy for invasive bladder cancer:the MGH experience[J].Eur Urol,2012,61(4):705-711.
[8]	Kulkarni GS,Hermanns T,Wei Y,et al.Propensity Score Analysis of Radical Cystectomy Versus Bladder-Sparing Trimodal Therapy in the Setting of a Multidisciplinary Bladder Cancer Clinic[J].J Clin Oncol,2017,35(20):2299-2305.
[9]	Arcangeli G,Strigari L,Arcangeli S.Radical cystectomy versus organ-sparing trimodality treatment in muscle-invasive bladder cancer:A systematic review of clinical trials[J].Crit Rev Oncol Hematol,2015,95(3):387-396.
[10]	Mak KS,Smith AB,Eidelman A,et al.Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer[J].Int J Radiat Oncol Biol Phys,2016,96(5):1028-1036.
[11]	Miyamoto D,Gibb E,Mouw K,et al.OC-0049:Genomic profiling of muscle invasive bladder cancer to predict response to chemoradiation therapy[J].Radiother Oncol,2018,127(S1):S21.
[12]	Efstathiou JA,Mouw KW,Gibb EA,et al.Impact of Immune and Stromal Infiltration on Outcomes Following Bladder-Sparing Trimodality Therapy for Muscle-Invasive Bladder Cancer[J].Eur Urol,2019,76(1):59-68.
[13]	Yang L,Williamson A,Irlam J,et al.,Molecular Subtyping of Muscle-Invasive Bladder Cancer Predicts Benefit of Hypoxia-Targeting Therapy[J].Int J Radiat Oncol Biol Phys,2017.99(2S):E222.
[14]	Stein JP,Lieskovsky G,Cote R,et al.Radical cystectomy in the treatment of invasive bladder cancer:long-term results in 1,054 patients[J].J Clin Oncol,2001,19(3):666-675.
[15]	Shah JB,McConkey DJ,Dinney CP.New strategies in muscle-invasive bladder cancer:on the road to personalized medicine[J].Clin Cancer Res,2011,17(9):2608-2612.
[16]	Choi W,Porten S,Kim S,et al.Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy[J].Cancer Cell,2014,25(2):152-165.
[17]	McConkey DJ,Choi W,Shen Y,et al.A Prognostic Gene Expression Signature in the Molecular Classification of Chemotherapy-naïve Urothelial Cancer is Predictive of Clinical Outcomes from Neoadjuvant Chemotherapy:A Phase 2 Trial of Dose-dense Methotrexate,Vinblastine,Doxorubicin,and Cisplatin with Bevacizumab in Urothelial Cancer[J].Eur Urol,2016,69(5):855-862.
[18]	Seiler R,Gibb EA,Wang NQ,et al.Divergent Biological Response to Neoadjuvant Chemotherapy in Muscle-invasive Bladder Cancer[J].Clin Cancer Res,2019,25(16):5082-5093.
[19]	Gust KM,Rebhan K,Resch I,et al.Immune checkpoint inhibition in muscle-invasive and locally advanced bladder cancer[J].Curr Opin Urol,2020,30(4):547-556.
[20]	Massard C,Gordon MS,Sharma S,et al.Safety and Efficacy of Durvalumab(MEDI4736),an Anti-Programmed Cell Death Ligand-1 Immune Checkpoint Inhibitor,in Patients With Advanced Urothelial Bladder Cancer[J].J Clin Oncol,2016,34(26):3119-3125.
[21]	Kim J,Kwiatkowski D,McConkey DJ,et al.The Cancer Genome Atlas Expression Subtypes Stratify Response to Checkpoint Inhibition in Advanced Urothelial Cancer and Identify a Subset of Patients with High Survival Probability[J].Eur Urol,2019,75(6):961-964.
[22]	Casadei C,Dizman N,Schepisi G,et al.Targeted therapies for advanced bladder cancer:new strategies with FGFR inhibitors[J].Ther Adv Med Oncol,2019,11:1758835919890285.
[23]	Liu X,Zhang W,Geng D,et al.Clinical significance of fibroblast growth factor receptor-3 mutations in bladder cancer:a systematic review and meta-analysis[J].Genet Mol Res,2014,13(1):1109-1120.
[24]	Robertson AG,Kim J,Al-Ahmadie H,et al.Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer[J].Cell,2017,171(3):540-556.e25.